Navigation Links
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.


    COMPANY CONTACTS                        MEDIA CONTACT

    Russell Skibsted                        Susan Neath

    SVP & Chief Business Officer            Porter Novelli Life Sciences

                                            619-849-6007

    Paul Arndt

    Manager, Investor Relations

    949-788-6700



    [1] FLOMAX is a registered trademark of Boehringer Ingelheim

    [2] CARDURA is a registered trademark of Pfizer, Inc.

    [3] HYTRIN is a registered trademark of Abbott Laboratories

    [4] PROSCAR is a registered trademark of MERCK & CO., Inc.

    [5] AVODART is a registered trademark of GlaxoSmithKline

CONTACT: Russell Skibsted, SVP & Chief Business Officer, or Paul Arndt,Manager, Investor Relations, both of Spectrum Pharmaceuticals, Inc.,+1-949-788-6700; or Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007, for Spectrum Pharmaceuticals, Inc.

Web site: http://www.spectrumpharm.com/

Ticker Symbol: (NASDAQ-NMS:SPPI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
(Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:7/28/2014)... With California in a record draught ... that a fire blanket that is over ... development by SunSeeker Enterprises, Inc. The fire blanket—utilizing the ... the extreme heat of re-entry into the Earth's atmosphere—will ... , “Our firefighters routinely lay their very lives on ...
(Date:7/28/2014)... July 28, 2014 At some point in ... where they’re forced to contact the authorities. Distinguishing the ... than it initially seems. , Not every dangerous situation is ... stolen, a person get mugged, or a bank get held ... leading onlookers to be more passive than they otherwise should. ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... July 28, 2014 The report ... Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, Animal ... to 2018” defines and segments the global industrial ... global value for industrial enzymes. It also identifies ... enzymes market with analysis of trends, opportunities, burning ...
(Date:7/28/2014)... School of Medicine (BUSM) report variants in a new ... Alzheimer,s disease (AD). The discovery of this novel genetic ... target PLXNA4 specifically. These findings appear in the ... frequent age-related dementia affecting 5.4 million Americans including 13 ... than 40 percent of people age 85 and older. ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2
... ... of the myESMO Professional Networking Community, an innovative online platform that offers society members ... ... European Society for Medical Oncology is today pleased to announce the launch of ...
... AWF calls on Gov. Parkinson to condemn and abandon such practices ... Alliance for Worker Freedom (AWF) calls on Kansas Governor Mark Parkinson ... resources and taxpayer money to obtain personal contact information of healthcare ... Kansas. , , Letters obtained by AWF, printed ...
... , SHENZHEN, China, Sept. 14 /PRNewswire-FirstCall/ - HTDS ... following update to its shareholders and followers on the ... subsidiary and other general business matters. , At the ... of Influenza A (H1N1) Vaccine (Split Virion). The company ...
... A popular stomach-acid reducer used to prevent stress ... increases the risk of those patients contracting pneumonia threefold, ... Medicine. Hospital-acquired pneumonia is the leading cause of ... stays by an average of seven to nine days, ...
... , LAS VEGAS, Sept. 14 EQ Labs, Inc. ... the Company held its first public stockholders, meeting at its headquarters ... of the Board and CEO presiding. The Board of Directors ... recommendations of the Board and the resolutions placed before the shareholders ...
... Sept. 14 Tupperware Brands Corporation,s highly successful Chain of ... to celebrate the importance of female friendship and the rewards that ... with organizations in local markets around the world who work to ... , , On September 17, 2009 ...
Cached Medicine News:Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 2Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 3Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 4Health News:Kansas Departments Use Taxpayer Money and State Resources to Collect Healthcare Workers' Names for the SEIU 2Health News:Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production 2Health News:Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production 3Health News:Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production 4Health News:Popular stomach acid reducer triples risk of developing pneumonia 2Health News:EQLB Releases Letter to Shareholders 2Health News:EQLB Releases Letter to Shareholders 3Health News:BeautiControl(R) Encompasses Tupperware Brands Global Women's Initiative: Chain of Confidence(R) 2
The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
...
...
... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
Medicine Products: